drugset
drugset / Trial / NCT00003516

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

NCT00003516 ↗

Phase 2 Terminated 16 enrolled Burzynski Research Institute
NaSingle-groupOpen-labelTreatment

Summary

Current therapies for Stage III or Stage IV Prostate Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage III or Stage IV Prostate Cancer. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Stage III or Stage IV Prostate Cancer.

Timeline

Start
1996-03-27
Primary completion
2004-03-18
Completion
2004-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Astugenal Unknown — Oral
Subject antineoplaston A10 Small molecule — Oral

Indications

prostate cancer